Because neurofilaments are neuron specific cytoskeletal proteins (Yuan et al., 2012) that can be released into extracellular fluid following axon injury (Petzold, 2005), in MS clinical settings a growing body of evidence support that neurofilament levels in cerebrospinal fluid (CSF) and serum are a reliable indicator of prognosis and treatment response and facilitate individual treatment decisions (Salzer et al., 2010; Teunissen and Khalil, 2012; Bittner et al., 2021). Here, DNM2 is linked to myeloid sarcoma.